Altimmune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. 

CEO
Jerome B. Durso
CEOJerome B. Durso
Employees
57
Employees57
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1997
Founded1997
Employees
57
Employees57

ALT Key Statistics

Market cap
561.06M
Market cap561.06M
Price-Earnings ratio
-3.09
Price-Earnings ratio-3.09
Dividend yield
Dividend yield
Average volume
2.65M
Average volume2.65M
High today
$2.95
High today$2.95
Low today
$2.84
Low today$2.84
Open price
$2.93
Open price$2.93
Volume
1.54M
Volume1.54M
52 Week high
$7.73
52 Week high$7.73
52 Week low
$2.56
52 Week low$2.56

Stock Snapshot

With a market cap of 561.06M, Altimmune(ALT) trades at $2.89. The stock has a price-to-earnings ratio of -3.09.

On 2026-06-03, Altimmune(ALT) stock moved within a range of $2.84 to $2.95. With shares now at $2.89, the stock is trading +1.6% above its intraday low and -2.2% below the session's peak.

Trading activity shows a volume of 1.54M, compared to an average daily volume of 2.65M.

The stock's 52-week range extends from a low of $2.56 to a high of $7.73.

The stock's 52-week range extends from a low of $2.56 to a high of $7.73.

ALT News

Investing.com 1d
Citizens reiterates Altimmune stock rating on fibrosis trial data - Investing.com

...

Citizens reiterates Altimmune stock rating on fibrosis trial data - Investing.com
TipRanks 6d
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide

Altimmune (ALT) announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor a...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

People also own

Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.